Catalent looks to cash in with $872m IPO
With its expected sale of 42.5m shares for $20.50 each, CDMO (contract development and manufacturing organization) Catalent is looking to become a public company.
News & Analysis on Clinical Trial Services & Contract Research And Development
- Home
- APIs (active pharmaceutical ingredients)
- Delivery formulations
- Delivery technologies
- Excipients, raw materials & intermediates
- Processing equipment
- QA/QC
- Regulations
- Tabletting, coating & ancillary equipment
- Analytical testing, QC
- Bulk ingredients
- Contract Manufacturing
- Contract sales & marketing
- Data management
- Drug delivery, formulation
- Fill & finish, packaging
- Medical Devices
- Phase I-II
- Phase III-IV
- Preclinical
- Regulatory affairs
- Supply chain, logistics
- Validation services
- Suppliers